Key facts
- This page summarizes Paul J. Mellett's Form 4 filing for ENANTA PHARMACEUTICALS INC (ENTA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2025, 16:37.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Tax liability
Additional SEC filing notes
Footnote F1
Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.
Footnote F2
Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.